Literature DB >> 22527665

[Emergencies in adult mucoviscidosis patients].

C Smaczny1, T Born, T O F Wagner.   

Abstract

Cystic fibrosis is an inherited autosomal recessive metabolic disease caused by mutations on the CFTR gene. This leads to defective chloride channels on epithelial cell membranes and causes various disorders of the respiratory, gastrointestinal, and urogenital tracts.As a result, all exocrine glands produce a viscous secretion, leading to pulmonary symptoms such as chronic cough, secretion retention, recurring infections as well as bronchiectasis and obstructive lung emphysema. Gastrointestinal effects include exocrine and often also endocrine pancreatic insufficiency with chronic diarrhea and maldigestion syndrome as well as pancreoprivic diabetes mellitus; biliary cirrhosis occurs in 10% of cases. Additional effects include reduced fertility in women and infertility in men.Life-threatening complications include bleeding from the bronchial arteries, pneumothorax, and distal intestinal obstruction syndrome (DIOS), previously known as meconium ileus equivalent. Treatment requires rapid diagnosis and should be carried out in experienced centres, since the mortality rate can otherwise be up to 50%.

Entities:  

Mesh:

Year:  2012        PMID: 22527665     DOI: 10.1007/s00108-012-3019-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  18 in total

Review 1.  Exacerbations in cystic fibrosis: 3--Management.

Authors:  A Smyth; J S Elborn
Journal:  Thorax       Date:  2008-02       Impact factor: 9.139

2.  Life threatening haemoptysis in cystic fibrosis: an alternative therapeutic approach.

Authors:  D Bilton; A K Webb; H Foster; P Mulvenna; M Dodd
Journal:  Thorax       Date:  1990-12       Impact factor: 9.139

3.  Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax.

Authors:  Patrick A Flume; Peter J Mogayzel; Karen A Robinson; Randall L Rosenblatt; Lynne Quittell; Bruce C Marshall
Journal:  Am J Respir Crit Care Med       Date:  2010-08-01       Impact factor: 21.405

4.  Pneumothorax in cystic fibrosis: a 26-year experience.

Authors:  M L Spector; R C Stern
Journal:  Ann Thorac Surg       Date:  1989-02       Impact factor: 4.330

5.  Small intestinal permeability and orocaecal transit time in cystic fibrosis.

Authors:  A M Dalzell; N S Freestone; D Billington; D P Heaf
Journal:  Arch Dis Child       Date:  1990-06       Impact factor: 3.791

6.  Pneumothorax in cystic fibrosis.

Authors:  Patrick A Flume; Charlie Strange; Xiaobu Ye; Myla Ebeling; Thomas Hulsey; Leslie L Clark
Journal:  Chest       Date:  2005-08       Impact factor: 9.410

7.  Percutaneous bronchial artery embolization in the management of massive hemoptysis in chronic lung diseases. Immediate and long-term outcomes.

Authors:  E Serasli; V Kalpakidis; K Iatrou; V Tsara; D Siopi; P Christaki
Journal:  Int Angiol       Date:  2008-08       Impact factor: 2.789

8.  Emergency lobectomy for massive hemoptysis in cystic fibrosis.

Authors:  D K Porter; M J Van Every; J W Mack
Journal:  J Thorac Cardiovasc Surg       Date:  1983-09       Impact factor: 5.209

Review 9.  Intensive care management of the patient with cystic fibrosis.

Authors:  Ted M Kremer; Robert G Zwerdling; Peter H Michelson; P O'Sullivan
Journal:  J Intensive Care Med       Date:  2008-04-28       Impact factor: 3.510

10.  Distal intestinal obstruction syndrome in adults with cystic fibrosis.

Authors:  Xavier Dray; Thierry Bienvenu; Nadine Desmazes-Dufeu; Daniel Dusser; Philippe Marteau; Dominique Hubert
Journal:  Clin Gastroenterol Hepatol       Date:  2004-06       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.